Interaction of Bortezomib with Cell Membranes Regulates Its Toxicity and Resistance to Therapy.

ABSTRACT: Bortezomib (BTZ) is a potent proteasome inhibitor currently being used to treat multiple myeloma. However, its high toxicity and resistance to therapy severely limit the treatment outcomes. Drug-membrane interactions have a crucial role in drugs' behavior in vivo, affecting their bioavailability and pharmacological activity. Additionally, drugs' toxicity often occurs due to their effects on the cell membranes. Therefore, studying BTZ's interactions with cell membranes may explain the limitations of its therapy. Due to the cell membranes' complexity, lipid vesicles were proposed here as biomembrane models, focusing on the membrane's main constituents. Two models with distinct composition and complexity were used, one composed of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and the oth

SUBMITTER: Ramalho MJ 

PROVIDER: S-EPMC9500884 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature